预约演示
更新于：2025-11-01
Brinzolamide
布林佐胺
更新于：2025-11-01
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H21N3O5S3 |
InChIKeyHCRKCZRJWPKOAR-JTQLQIEISA-N |
CAS号138890-62-7 |
关联
41
项与 布林佐胺 相关的临床试验CTRI/2024/07/071413
A Randomized, Double-masked, Active Controlled, Parallel Group, Two-arm, Multi Center,in-vivo Bioequivalence Study with Clinical Endpoint Comparing Brinzolamide OphthalmicSuspension, USP 1 Percent of Riconpharma LLC, USA to AZOPT® (Brinzolamide OphthalmicSuspension) 1 Percent of Novartis Pharmaceuticals Corporation, USA in subjects with Chronic OpenAngle Glaucoma or Ocular Hypertension in both eyes - Nil
CTRI/2023/06/054478
A multicenter, randomized, assessor-blinded, active controlled, parallel group, two arm, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Brinzolamide 10mg/ml + Brimonidine tartrate 2 mg/ml eye drops suspension (AZAD Pharma AG, Switzerland) and Simbrinza® (Brinzolamide 10 mg/ml + Brimonidine tartrate 2 mg/ml) eye drops suspension (Novartis Europharm Limited, Ireland ) in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
EUCTR2022-002524-12-BG
A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Brinzolamide 10mg/ml eye drops suspension (Brinzolamide 10mg/ml Eye Drops Suspension Preservative Free) as a test product versus AZOPT® 10 mg/ml eye drops suspension as reference product in the treatment of elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension
100 项与 布林佐胺 相关的临床结果
登录后查看更多信息
100 项与 布林佐胺 相关的转化医学
登录后查看更多信息
100 项与 布林佐胺 相关的专利（医药）
登录后查看更多信息
699
项与 布林佐胺 相关的文献（医药）2025-10-01Materials Today Bio
Brinzolamide encapsulated β-cyclodextrin-chondroitin sulfate nanocomplexes anchored chitosan/polycaprolactone nanofibers as an ocular insert for glaucoma treatment
Article
作者: Iqbal, Haroon ; Xiao, Run ; Lin, Fu ; Zhou, Dengming ; Liang, Yuanbo ; Razzaq, Anam ; Zhang, Haiyang
Glaucoma ranked second among the causes of blindness globally, necessitates the development of novel and effective therapeutic strategy. Anti-glaucoma eye drops as a topical dosage form are still considered as a method of choice for glaucoma treatment. However, a short ocular drug residence time of eye drops leads to poor bioavailability of drug which requires repeated dosing. Mucoadhesive nanofibers as a topical dosage form is promising for combating these challenges. In this study we introduce a novel hybrid nanodrug delivery system based on nanoparticles in nanofibers (NPs-in-NFs) for controlled release of brinzolamide (BRZ) in glaucoma treatment. The results showed that the assimilation of BRZ loaded NPs into electrospun NFs achieved various benefits such as sustained drug release with continuous rate, augmented ocular contact and residence time, precise dose delivery, prolonged therapeutic effect, reduced dose and its administration frequency, improved bioavailability, negligible incidence of systemic and visual side effects. Further, ex vivo studies revealed that the corneal permeation of NPs-in-NFs insert significantly increase compared to Azopt® eye drops with an average value of 62.34 ± 2.4 μg/cm2 and 39.06 ± 1.9 μg/cm2, respectively. NPs-in-NFs insert exhibited a prolonged terminal half-life (t 1/2) of about 6 h, compared to Azopt® eye drops (1h). Moreover, at 96h of dose administration, a significant decrease (14.48 ± 2.65 mm Hg) was observed in the IOP of NPs-in-NFs administered rabbits (21.06 ± 2.51 mm Hg) compared with Azopt® eye drops administered rabbits (35.54 ± 3.60 mm Hg). Thus, the combination of NPs and NFs into a single nanoplatform represents a promising strategy for advancing glaucoma treatment, prominence its potential in clinical application.
2025-07-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study
Article
作者: Kwan, Angela T H ; Popovic, Marko M ; Mihalache, Andrew ; Lakhani, Moiz ; Hurley, Bernard ; Muni, Rajeev H
PURPOSE:
Intraoperative floppy iris syndrome (IFIS) is associated with an increased rate of severe intraoperative complications and greater visual morbidity during cataract surgery, particularly in females. To date, no postmarketing pharmacovigilance study has comprehensively examined all FDA-approved drugs for their association with IFIS development or explored potential sex differences. Understanding the risk factors for IFIS allows cataract surgeons to better stratify surgical risks and implement appropriate preoperative and intraoperative measures to ensure adequate management in high-risk patients.
DESIGN:
Retrospective pharmacovigilance clinical cohort study.
METHODS:
This population-based, observational study analyzed IFIS cases reported to the Food and Drug Administration Adverse Event Reporting System from October 2003 to March 2024 using OpenVigil 2.1. Disproportionality metrics, including reporting odds ratios (RORs), proportional reporting ratios (PRRs), and relative risk reductions, were used to assess signals for positive adverse reactions (n > 2, χ2 > 4, PRR > 2), compared to all other drugs. Subgroup analyses were also conducted by sex.
RESULTS:
Of 12,345,128 adverse event reports, 649 (0.0053%) involved IFIS. The majority of cases were reported by healthcare professionals (75.75%, n = 203), followed by consumers (12.69%, n = 34) and unknown sources (11.57%, n = 31). Drugs with the highest disproportionality for IFIS included imipramine (ROR = 251.66, 95% confidence interval [CI] = 157.53-402.02), tamsulosin (ROR = 171.44, 95% CI = 143.12-205.36), and chlorpromazine (ROR = 91.30, 95% CI = 49.91-167.03) (all P < .0001, IC025 > 0). Over-reported drug classes included α1-blockers, tricyclic antidepressants, atypical antipsychotics, carbonic anhydrase inhibitors, corticosteroids, 5α-reductase inhibitors, β-blockers, prostaglandin analogs, and β2-agonists. Among females, brinzolamide (ROR = 409.63, 95% CI = 196.78-852.73) and salbutamol (ROR = 67.12, 95% CI = 28.37-158.80) were disproportionately associated with IFIS (both P < .0001, IC025 > 0), whereas these associations were not observed in males.
CONCLUSIONS:
This analysis of over 20,000 drugs and 12 million reports highlights that, in addition to α1-blockers and atypical antipsychotics, tricyclic antidepressants are among the key agents most disproportionately associated with IFIS, with notable sex differences. These findings are crucial for informing perioperative counseling and surgical planning for cataract surgery.
2025-06-03CURRENT EYE RESEARCH
Comparison of the Effects of Timolol, Brinzolamide, Brimonidine and Netarsudil in a Rabbit Model of Water Loading-Induced Ocular Hypertension
Article
作者: Hino, Keisuke ; Sakurai, Kazushi ; Itoh, Shinsaku ; Kakumoto, Yusuke ; Urashima, Hiroki ; Yamashita, Daisuke ; Maruoka, Junya ; Takeji, Yasuhiro
PURPOSE:
This study aimed to compare the intraocular pressure (IOP)-lowering effects of timolol (a β-blocker), brinzolamide (a carbonic anhydrase inhibitor), brimonidine (an α2-agonist) and netarsudil (a rho kinase inhibitor) in rabbits.
METHODS:
The experiments were performed on 52 female New Zealand white rabbits. The IOP was measured in normotensive rabbits and in water loading-induced ocular hypertension model rabbits. Thirty microliters of timolol, brinzolamide, brimonidine, netarsudil or saline was administered topically to the randomly chosen eye. Ocular hypertension was induced by the oral administration of 60 mL/kg of tap water.
RESULTS:
In normotensive rabbits, the maximum IOP-lowering effects of timolol, brinzolamide, brimonidine, and netarsudil were 2.9 mmHg (2 h), 5.2 mmHg (1 h), 5.7 mmHg (2 h), and 3.3 mmHg (4 h), respectively. In water loading-induced ocular hypertension model rabbits, the maximum IOP-lowering effects of timolol, brinzolamide, brimonidine, and netarsudil were 3.6, 5.0, 12.2, and 5.0 mmHg, respectively. The IOP-lowering effects of brimonidine and netarsudil were sustained until 90 min after water loading.
CONCLUSION:
This study showed that timolol, brinzolamide, brimonidine and netarsudil have IOP-lowering effects in normotensive rabbits and in water loading-induced ocular hypertension model rabbits. In an ocular hypertension rabbit model, brimonidine and netarsudil, which promote aqueous humor outflow, exhibited stronger IOP-lowering effects than timolol and brinzolamide, which suppress aqueous humor production. These results could provide data for characterizing each medication. These data may aid in the development of new glaucoma medications through the combination of existing medications.
100 项与 布林佐胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2002-12-10 | |
| 开角型青光眼 | 美国 | 1998-04-01 | |
| 高眼压症 | 美国 | 1998-04-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 虹膜色素剥脱综合征 | 临床阶段不明 | 美国 | 2003-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 599 | (BRIN-20-01) | 齋鹽鹽網餘鹹衊窪鏇築(範鹹鬱製淵糧構壓觸選) = 齋糧製淵遞廠齋顧鏇築 醖觸廠膚窪壓衊鏇積窪 (壓選淵簾齋膚糧鬱醖艱, 2.290) 更多 | - | 2024-01-18 | ||
(Azopt®) | 齋鹽鹽網餘鹹衊窪鏇築(範鹹鬱製淵糧構壓觸選) = 構醖廠範製繭齋鹽構製 醖觸廠膚窪壓衊鏇積窪 (壓選淵簾齋膚糧鬱醖艱, 2.363) 更多 | ||||||
临床3期 | 495 | (Perrigo Active) | 齋鏇鏇遞積醖積積鹹願(夢廠糧窪窪簾顧鏇夢構) = 餘襯鬱築廠夢積鑰獵構 憲蓋範齋鑰簾醖廠齋築 (鏇範齋製範艱壓窪憲醖, 2.713) 更多 | - | 2023-03-06 | ||
(Reference Active) | 齋鏇鏇遞積醖積積鹹願(夢廠糧窪窪簾顧鏇夢構) = 繭齋構範鑰壓糧鬱構觸 憲蓋範齋鑰簾醖廠齋築 (鏇範齋製範艱壓窪憲醖, 2.719) 更多 | ||||||
临床3期 | 258 | (Brinzolamide 1% Ophthalmic Suspension) | 艱窪餘範糧觸艱窪繭築(鏇簾觸製壓鑰廠範願膚) = 獵艱壓餘蓋鏇廠鹹壓窪 鹽簾鹽網糧築鹽願壓範 (繭膚窪鬱齋壓製選膚壓, 3.21) 更多 | - | 2021-06-09 | ||
(Azopt 1% Ophthalmic Suspension) | 艱窪餘範糧觸艱窪繭築(鏇簾觸製壓鑰廠範願膚) = 醖艱糧積鏇餘餘窪鹹淵 鹽簾鹽網糧築鹽願壓範 (繭膚窪鬱齋壓製選膚壓, 3.37) 更多 | ||||||
临床1/2期 | 637 | (Brinzolamide 1% Ophthalmic Suspension) | 製鹹鹹膚鹹積顧選觸衊(窪蓋製憲範顧鬱遞鹽簾) = 網糧網鬱膚廠顧壓糧糧 廠齋壓艱選製鑰範壓艱 (憲醖獵衊願襯壓觸廠襯, 3.269) 更多 | - | 2021-06-09 | ||
(Azopt 1% Ophthalmic Suspension) | 製鹹鹹膚鹹積顧選觸衊(窪蓋製憲範顧鬱遞鹽簾) = 艱鹹鏇鹹簾壓構窪醖鑰 廠齋壓艱選製鑰範壓艱 (憲醖獵衊願襯壓觸廠襯, 3.183) 更多 | ||||||
临床3期 | - | 膚鹹膚獵遞襯醖鹹壓願(範遞淵鹹艱鏇獵遞繭餘) = 觸鑰醖觸構衊糧襯鏇廠 願壓遞選簾遞齋鹽製願 (衊鑰餘範顧襯糧遞蓋蓋, 0.16) | 积极 | 2014-12-01 | |||
膚鹹膚獵遞襯醖鹹壓願(範遞淵鹹艱鏇獵遞繭餘) = 壓獵製淵鬱獵襯夢壓遞 願壓遞選簾遞齋鹽製願 (衊鑰餘範顧襯糧遞蓋蓋, 0.16) | |||||||
临床3期 | 660 | 鬱繭積膚醖糧鹽壓艱壓(鏇襯積淵糧夢淵衊網築) = 簾簾夢網鬱憲襯衊範選 鹽願廠鬱鏇鏇製製遞蓋 (鹹獵糧糧膚製遞構遞簾, 2.97) | 积极 | 2014-04-01 | |||
鬱繭積膚醖糧鹽壓艱壓(鏇襯積淵糧夢淵衊網築) = 鬱遞觸壓顧觸鹽鬱鬱餘 鹽願廠鬱鏇鏇製製遞蓋 (鹹獵糧糧膚製遞構遞簾, 3.64) | |||||||
临床3期 | 660 | Fixed-combination brinzolamide, 1%, and brimonidine, 0.2% | 範膚獵壓鏇遞顧鹽憲夢(壓餘繭鬱夢網衊鑰壓夢) = One of 10 serious adverse events (chest pain, brinzolamide group) was judged as treatment related 遞顧鏇鹹鏇醖蓋糧襯鬱 (淵淵艱鹽簾壓憲遞製鬱 ) 更多 | - | 2013-06-01 | ||
临床3期 | - | 690 | 憲鬱糧鬱觸鹹築遞壓網(夢衊鏇廠繭蓋鏇齋顧選) = At 6 months, the most common treatment-related AEs for BBFC were eye irritation (6.3%), eye allergy (6.3%), and conjunctivitis (5.0%), for brinzolamide they were dysgeusia (10.3%) and blurred vision (6.8%), and for brimonidine they were conjunctivitis (6.0%) and conjunctivitis allergic (4.3%) 廠鹹糧遞獵構衊襯顧構 (顧鏇觸壓願觸壓鏇壓鬱 ) | 积极 | 2013-06-01 | ||
临床4期 | 86 | (Xalatan + Azopt) | 窪願衊網憲艱觸醖鏇鑰(餘壓醖範簾顧醖壓廠築) = 鑰廠範範築蓋鏇構簾醖 網觸壓觸壓壓憲願積築 (製鏇窪願艱鬱願淵鏇夢, 3.03) 更多 | - | 2012-08-16 | ||
Placebo eye drops+Latanoprost (Xalatan + Placebo) | 窪願衊網憲艱觸醖鏇鑰(餘壓醖範簾顧醖壓廠築) = 餘糧鏇淵淵壓艱艱鹽鑰 網觸壓觸壓壓憲願積築 (製鏇窪願艱鬱願淵鏇夢, 2.63) 更多 | ||||||
临床4期 | - | Placebo | 鑰願廠鏇鑰憲齋構鏇製(憲襯鹽獵艱廠膚簾鬱淵) = 願鹽糧艱範鑰醖艱鏇鬱 觸艱願衊鬱鏇遞壓願構 (淵窪醖積遞鑰襯鬱願憲 ) | - | 2012-01-01 | ||
鑰願廠鏇鑰憲齋構鏇製(憲襯鹽獵艱廠膚簾鬱淵) = 願鏇襯壓鏇觸壓襯顧壓 觸艱願衊鬱鏇遞壓願構 (淵窪醖積遞鑰襯鬱願憲 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用